⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5693195 | 0.97 | — | — | |
| SCHEMBL9508954 | 0.78 | — | — | |
| SCHEMBL1440631 | 0.77 | — | — | |
| SCHEMBL3844302 | 0.77 | NOS3 (0.32) | — | |
| SCHEMBL1127413 | 0.77 | NOS3 (0.32) | — | |
| SCHEMBL20315224 | 0.77 | — | — | |
| SCHEMBL21648271 | 0.75 | — | — | |
| SCHEMBL457323 | 0.75 | — | — | |
| SCHEMBL9508961 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL2807165 | 0.75 | NOS3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023165382-A1 | USE OF ACYLTADINE COMPOUND HAVING GLYCOSIDASE INHIBITORY ACTIVITY | 上海临贤生物科技有限公司 | 2023-09-07 | — | — | WO | disclosed |
| WO-2023165381-A1 | ACYL-BASED STATIN COMPOUND WITH LIPASE INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海临贤生物科技有限公司 | 2023-09-07 | — | — | WO | disclosed |
| EP-3430017-B1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | UNIV CALIFORNIA (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022099011-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021257736-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021042039-A1 | SYNTHETIC ANTIMICROBIAL PEPTIDES | AJK PHARMACEUTICAL LLC (US) | 2021-03-04 | — | — | WO | disclosed |
| US-9834534-B2 | Neuraminidase inhibitor compounds, compositions and methods for the use thereof in anti-viral treatments | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-12-05 | — | — | US | disclosed |
| WO-2015164289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| EP-2824097-A1 | Prolinamide derivative as thrombin inhibitor, preparation method and application thereof | Shanghai Institute of Pharmaceutical Industry (CN) | 2015-01-14 | — | — | EP | disclosed |
| EP-2639230-A1 | PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Pharmaceutical Industry (CN) | 2013-09-18 | — | — | EP | disclosed |
| US-8349051-B2 | Ion exchange resin and a process for the use thereof | CLEAN TEQ PTY LTD (AU) | 2013-01-08 | — | — | US | disclosed |
| WO-2009145814-A9 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100058893-A1 | ION EXCHANGE RESIN AND A PROCESS FOR THE USE THEREOF | CLEAN TEQ PTY LTD (AU) | 2010-03-11 | — | — | US | disclosed |
| EP-2146996-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | AstraZeneca AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009145814-A2 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |